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INTRODUCTION
            Periocular and Orbital injections of long-acting corticosteroids are 
being used to treat  inflammatory conditions of the eye for many years1,  2  . 
However it has been suggested that peribulbar injection may not be adequate 
to treat chronic ocular disease because their action is partly due to systemic 
absorption of the drug and their  effectiveness lasts  only for a few days to 
weeks3. Intraocular administration has the potential to deliver steroids at high 
local concentrations
             The safety of intravitreal steroid preparations has been studied in  
animal models. Dexamethasone has been shown to be safe in both primates 
and humans. Doses of up to 1 mg were well tolerated in rabbits and caused no 
permanent  changes  in  the  ERG  or  the  retinal  histology.  However 
Dexamethasone sodium phosphate is soluble and has a short half life of about 
3 days4,5. In contrast triamcinolone acetonide is hydrophobic and appears to 
provide  therapeutic  levels  in  the  vitreous  for  up  to  3  months6.  Based  on 
experimental  studies  by  Machemer  and coworkers7,8 and  other  researchers, 
intravitreal triamcinolone acetonide has increasingly been used as treatment 
for intraocular proliferative, edematous, and neovascular diseases. Intravitreal 
triamcinolone has recently been shown to be nontoxic to the human retina and 
well  tolerated9,10.  It  has  shown  promising  results  in  uveitic11 and 
pseudophakic12 cystoid macular edema resistant to other treatments and also in 
resolving exudative retinal detachments in Vogt Koyanagi Harada syndrome13. 
Efficacy has also been reported in cystoid Macular edema caused by central 
retinal vein occlusion14, ischemic branch retinal vein occlusion15 and diabetic 
maculopathy17.
          Despite good initial anatomical and functional visual response to 
intravitreal triamcinolone when used in these conditions, macular edema has 
been  reported  to  recur  following  treatment,  often  necessitating  repeated 
injections15.  The  efficacy  in  age  related  macular  degeneration  is  not  very 
clear16. An antiangiogenic effect has been noted, but the gain in visual acuity 
has  not  been very  impressive18.  Danis  et  al.  ,  however  noted  a  short-term 
improvement  in  visual  acuity  and  fundus  findings  in  exudative  macular 
degeneration  following  intravitreal  injection  of  4mg  of  triamcinolone 
acetonide19.
          As the applications of triamcinolone expand, there is a growing interest 
in the safety of corticosteroid injections20. There does not appear to be much, 
if any of demonstrable toxicity after intravitreal injection of triamcinolone21. 
Side effects however appear in the long term. The major side effects include 
procedure-related  side  effects  (e.g.  pain  etc),  steroid-induced  intraocular 
pressure rise, cataract, vascular occlusions21, pseudohypopyon22, infectious and 
non-infectious  endophthalmitis23.  An  incidence  of  15-20%  of  clinically 
significant  cataract  that  eventually  underwent  cataract  surgery  has  been 
reported within a year of intravitreal injection of triamcinolone acetonide24. An 
incidence of 26.2% cataract surgery has been reported by Cekic et al25. 
           Noninfectious  endophthalmitis  and  pseudohypopyon  probably 
represent dispersion of triamcinolone crystals in the vitreous and the anterior 
chamber. The incidence has been reported to range from 0.2% to 1.6%. The 
majority  resolve  spontaneously22.  Nevertheless  such cases  need  to  be  kept 
under close observation.  
        A rise in the intraocular pressure is among the most serious of side  
effects. Jonas reported an incidence of 50% of eyes starting 1 to 2 months after 
an intravitreal  injection of 25mg of triamcinolone acetonide27.  Bakri  et al , 
noted an IOP rise in 48.8% with high levels reached in 27.9%. The mean time 
to reach the peak IOP was 6.6 weeks. These levels were noted to be higher 
than those reported for topical and posterior sub-Tenon steroids26. While all 
patients  in  Bakri’s  study had pressures  reversed by medication,  intractable 
glaucoma has also been reported28, 29.. These cases needed to be further treated 
with either a filtering surgery or vitrectomy with removal of the intravitreal 
steroid.
         Smithen et al, in a study of 89 patients found that the peak IOP rise was 
reached a mean of 96.7days from the intravitreal injection. They also noted 
that the slope of survival plot curves did not flatten with increasing follow-up, 
which meant that  the patients  may be at  risk for  pressure elevations for  a 
prolonged period of time30. 
         Triamcinolone acetonide has been noted to provide therapeutic levels in 
the vitreous for about three months6,  9. Because the durations of effects and 
side effects may outlast the intraocular availability, a closer follow up of these 
patients is needed to detect an IOP rise31.  A follow up time of 6 months has 
been fixed for our study. 
HISTORICAL PERSPECTIVE
         Intravitreal injection has been used in the treatment of human ocular 
disease for nearly a century. Initially reported in 1911 by Ohm32, as a means to 
introduce air for retinal tamponade and repair of detachment, the intravitreal 
administration of pharmaceutical agents was pioneered in the mid 1940’s with 
the use of penicillin to treat endophthalmitis
        Blankenship et al62, demonstrated in 1991, that Dexamethasone was well 
tolerated but of no therapeutic value for post vitrectomy treatment of diabetic 
retinopathy.  In  1995,  Penfold  et  al,16 in  a  pilot  study  demonstrated  that 
triamcinolone acetonide; a longer acting corticosteroid was well tolerated in 
patients  with  exudative  ARMD.  From  that  time  onwards,  intravitreal 
triamcinolone acetonide as an ophthalmic tool is gaining rapid popularity and 
acceptability among physicians in treating conditions such as macular edema, 
choroidal neovascularization.
        The ease of delivery, ease of availability besides the promise of success  
makes it both a potential sight saver and also a much inappropriately overused 
modality  with  devastating  complications.  Hence  an  investigation  into  the 
safety and efficacy of intravitreal triamcinolone of intravitreal triamcinolone is 
much needed
REVIEW OF LITERATURE
Studies on intravitreal triamcinolone injection
1. Cardillo  JA et  al.,in  his  study on Comparison of  intravitreal  versus 
posterior sub-Tenon's capsule injection of triamcinolone acetonide for 
diffuse diabetic macular edema states that intravitreal and Sub-Tenon's 
capsule injections of triamcinolone acetonide may be equally tolerated, 
with short-term performance clearly  favoring the  intravitreal  (4  mg) 
more  than  the  SBT  capsule  (40  mg)  route  for  the  anatomic  and 
functional  aspects  of  improvement  tested  in  this  investigation.and 
intravitreal  injection  did  not  show  any  significant  rise  in  IOP. 
(Ophthalmology. 2005 ;112:1557-63).
2. Jonas  JB  in  his  study  on  Intravitreal  triamcinolone  acetonide  for 
treatment  of  intraocular  proliferative,exudative,  and  neovascular 
diseases  concluded  that  complications  of  intravitreal  triamcinolone 
therapy  include  secondary  ocular  hypertension  in  about  40% of  the 
eyes  injected,  cataractogenesis,  postoperative  infectious  and  non-
infectious  endophthalmitis,  and  pseudo-endophthalmitis  and 
Intravitreal  triamcinolone  acetonide  may  offer  a  possibility  for 
adjunctive  treatment  of  intraocular  edematous  and  neovascular 
disorders. The duration of the effect of a single intravitreal injection of 
triamcinolone  depended on the  dosage  given.  Given in  a  dosage  of 
about 20mg to non-vitrectomized eyes, the duration of the effect and of 
the side-effects was 6-9 months (Prog Retin Eye Res. 2005 ;24:587-
611).
3. Ozkiris  A  et  al.,  after  analyzing  the  complications  of  intravitreal 
triamcinolone given for various reasons had concluded that the most 
common  complication  encountered  during  follow-up  was  transient 
elevation of IOP above 21mmHg (20.8%) and The mean IOP values at 
1, 3 and 6 months were statistically significantly higher than the mean 
preinjection value (p < 0.001).( Can J Ophthalmol. 2005 ; 40:63-8).
4. Jonas JB et al., in his analysis after intravitreal injection of 20mg of 
tricort found that Mean IOP started to rise 1 week after injection and 
returned to baseline values approximately 8 to 9 months after injection. 
Younger  age  (P  =  0.029)  was  significantly  associated  with 
triamcinolone-induced  ocular  hypertension.Triamcinolone  responders 
and triamcinolone nonresponders did not vary significantly in gender (P 
= 0.42), refractive error (P = 0.86), diabetes mellitus status (P = 0.74), 
and reason for treatment(Ophthalmology. 2005 ;112:593-80).
5. Ozkiris  A  et  al.,  evaluated  the  effectiveness  of  intravitreal 
triamcinolone  acetonide  as  primary  treatment  of  macular  edema  in 
branch  retinal  vein  occlusion  and  compared  with  patients  who  had 
received  laser  treatment  found  that  the  mean  edema  map  value  of 
Group 1 significantly decreased by 40% at 6-month examinations when 
compared with preinjection value(p<0.001). In Group 1, mean increase 
in intraocular pressure elevation was 19.8%at the 1-month, 26.9% at 3-
month,  and  5.7%  at  6-month  visits,  but  intraocular  pressures  were 
under  control  with  topical  antiglaucomatous  medications.(Eur  J 
Ophthalmol.2005;15:96-101).
6. Smithen LM et al., analyzed the incidence of intraocular pressure (IOP) 
elevation following intravitreal triamcinolone injection and concluded 
that IOP elevation after intravitreal triamcinolone injection is common 
and may take an extended period of time to manifest. The proportion of 
patients who developed a pressure elevation to atleast 24 mm Hg was 
much higher for those with baseline IOP 15 mm Hg or greater. (Am J 
Ophthalmol. 2004 ;138:740-3).
7. Gillies MC et al., determined the safety of a single intravitreal injection 
of triamcinolone acetonide (4 mg) in patients with subfoveal choroidal 
neovascularization  caused  by  age-related  macular  degeneration  and 
found that Triamcinolone-treated eyes had a significantly increased risk 
of developing mild or moderate elevation of the intraocular pressure. 
Topical  glaucoma  medication  reduced  intraocular  pressure  to 
acceptable levels in all patients. There was significant progression of 
cataract  in  the  triamcinolone-treated  eyes.(Arch  Ophthalmol.  2004  ;
122:336-40).
8. Bakri SJ et al., in his study on The effect of intravitreal triamcinolone 
acetonide  on  intraocular  pressure  concluded  that  A  single  4-mg 
intravitreal  triamcinolone  acetonide  injection  is  associated  with  an 
increase in IOP of 10 mm Hg or greater in 27.9% of eyes after the first 
injection.  All  eyes  responded  to  topical  glaucoma  medication. 
(Ophthalmic Surg Lasers Imaging. 2003 ;34:386-90).
9. Wingate  RJ  et  al.,  in  his  study  on  intravitreal  triamcinolone  and 
intraocular pressure concluded that  Approximately 30% of the study 
group  developed a  significant  rise  (>  or  =5 mm Hg)  in  intraocular 
pressure  above  baseline  during  the  first  3  months.  (Aust  N  Z  J 
Ophthalmol. 1999;27:431-2).
10. Khairallah M et al ., in his study on Primary intravitreal triamcinolone 
acetonide  for  diabetic  massive  macular  hard  exudates  found  that 
Intravitreal  injection  of  triamcinolone  acetonide  appears  to  be 
beneficial for reducing hard exudates, decreasing fluorescein leakage, 
and  significantly  improving  visual  acuity  in  patients  with  diabetic 
massive hard exudates. Visual improvement may not be important due 
to  profound  anatomical  impairment  caused  by  hard  exudates 
deposition.  Intraocular  pressure  elevation  occurred  in  25% and  was 
successfully treated by topical medication (Retina. 2005;25:835-9)
 
PHARMACOLOGY
Triamcinolone acetonide is  a  potent,  relatively  insoluble steroid that 
has  been used  for  treatment  of  ocular  inflammation  by peribulbar  or  sub-
tenon’s injection for decades3 Intravitreal administration of the drug offers the 
potential to deliver corticosteroids at high local concentrations for extended 
periods.  Studies  have  suggested  that  Periocular  administration  may  not  be 
adequate  for  chronic  ocular  diseases.  Part  of  the  effect  is  due to  systemic 
absorption of the drug. Also the therapeutic effectiveness lasts only for a few 
days to weeks3.
          Recently Cardillo et al., noted that intravitreal triamcinolone yielded 
superior  results  when  compared  with  posterior  sub-tenon’s  injection  at  1 
month and 3 months with respect to macular thickness and visual acuity32.
        Conway  et  al.,12 reported  benefit  with  intravitreal  injections  of 
triamcinolone in patients who were resistant to topical and Periocular steroid 
injections.  It  is  possible  that  these  are  dose-related  phenomena  with 
intravitreal steroids delivering higher concentrations to the retina12.
        The physical and biochemical properties of triamcinolone acetonide 
make it the ideal drug for intravitreal injections.
The physical properties:
            1. Water insoluble
            2. Particulate.
            3. Visible.
            4. Non toxic
            5. Longer retention time. 
Chemical structure of Triamcinolone Acetonide:
PHARMACOKINETICS
The study on the pharmacokinetics of the intravitreal steroid gives an 
insight to the possible duration of the therapeutic effect. Drug concentrations 
in the vitreous is determined not only by the amount of drug given, but also by 
the  distribution  and  clearance  of  such  compounds.  The  pharmacokinetic 
characteristics depend on the anatomical and physiological features at the site 
of administration and the physiochemical properties of the agent administered. 
Little  is  known  about  the  effect  of  age  on  the  disposition  of  compounds 
administered directly into the vitreous. 
Studies on pharmacokinetics:
Schindler and co-workers 34  evaluated the clearance rate of intravitreal 
triamcinolone  acetonide  injection  in  a  rabbit  model  by  performing  both 
ophthalmoscopy and colorimetric tests to determine the clearance of 0.5 mg of 
drug  injected  into  rabbit  eyes  that  underwent  no  surgery,  vitrectomy,  or 
vitrectomy combined with lensectomy. They found that in eyes that had no 
surgery the drug persisted for a long period.
Scholes  et  al35.,  in  their  animal  experiment  found  out  that  the 
ophthalmoscopic presence of white crystals of triamcinolone may not correlate 
with therapeutic triamcinolone acetonide levels.
The  human  study  done  by  Beer  et  al.36,  concluded  that  the  mean 
elimination for nonvitrectomised eyes was 18.6 days while for vitrectomised 
eyes  was  only  3.2  days.  Given  the  calculated  half-  life,  a  single  4  mg 
intravitreal injection of triamcinolone could be expected to last approximately 
three months in a non vitrectomised eye.
Neither study attempted to identify the route of elimination of the drug 
from the eye or the level of the compound that could be achieved in various 
compartments after intravitreal injection. The possibility for rapid elimination 
in  vitrectomised  subjects  could  be  surgically  induced  changes  affecting 
elimination via the anterior or posterior routes or the differences in the rates of 
triamcinolone crystal dissolution resulting from the free flow in the vitreous 
cavity not present in the absence of surgery .
DURATION OF ACTION
        After a single intravitreal injection of 25mg, triamcinolone acetonide 
was detected in low, but measurable concentrations up to 1.5 years in aqueous 
samples. No difference between phakic and pseudophakic patients was found. 
No  correlation  with  the  specific  retinal  disease  status  was  found  either30. 
Triamcinolone acetonide crystals can remain visible in the eye at least up to 9 
months after the injection37. Beer and associates noted a mean elimination half 
life of 18.6 days after an intravitreal injection of 4 mg in nonvitrectomised eyes 
which  means  that  measurable  concentrations  would  be  expected  to  last  for 
approximately  3  months36.  Thus  it  appears  that  there  is  dose  dependant 
retention  in  the  vitreous  cavity  with  higher  doses  being  retained  for  longer 
periods30. Therapeutic levels appear to be present in the vitreous for about three 
months6, 38     
Safety of an intravitreal injection of triamcinolone  :
      Triamcinolone has been shown to be safe in monkeys and has no effect on 
the  histopathology  and  electroretinogram  in  rabbit  retina.9,39 Hida  et  al., 
investigated  the  effects  of  the  vehicles  available  in  commercial  preparations 
alone without the steroid. They found the vehicle to be devoid of toxic effects40. 
In humans, injections of up to 25mg of triamcinolone acetonide has been shown 
to be devoid of retinal toxicity in vitrectomised and nonvitrectomised eyes 9,40.  
MECHANISM OF ACTION
       Intravitreal steroids have shown promise in reducing inflammation in 
animal models of endophthalmitis, uveitis and proliferative vitreoretinopathy 
and have been used in  pilot  studies  in  humans and could  therefore,  be  of 
potential use in refractory uveitis4, 6,11. 
       Corticosteroids  inhibit  prostaglandin  and  leukotriene  synthesis  by 
inhibiting phospholipase  A,  thereby inducing an anti-inflammatory  effect41. 
Furthermore they reverse capillary permeability, stabilize blood vessels and 
the blood-retinal barrier42-49  thereby also reducing exudation45  and inhibit the 
expression of inflammatory adhesion molecules46. 
        Many  corticosteroids  have  been  shown to  be  potent  inhibitors  of 
neovascularization  in  animal  models  and  are  among  the  most  potent 
antiangiogenic agents known  5,  19. The mechanism of steroid angioinhibition 
has  been shown to  be  an  effect  on  vascular  endothelial  cell  extra  cellular 
matrix turnover as well as inhibition of inflammatory cells, which invariably 
precipitate an inflammatory response 47,48.
          It is however possible that the usual mechanisms alone may not be at 
work when an intravitreal injection is given .34 In this situation the doses used 
are far in excess of those necessary to activate corticosteroid receptors and 
also  include  inhibition  of  lipid  per  oxidation  and  hydrolysis  that  damages 
neuronal and micro vascular membranes after injury.37 This may explain their 
efficacy  in  conditions  that  are  otherwise  resistant  to  conventional  steroid 
administration12.    
 The proposed mechanisms in macular edema include–
                       1. Increases the integrity of blood ocular barrier
                       2. Decreased capillary permeability
                       3. Decreases local availability of chemical mediators
                       4. Causes vasoconstriction of capillaries
                       5. Increased diffusion by modulation of Ca++ channel
                       6. Decreased VEGF
                       7. Decreases the cystic spaces 
 Triamcinolone acetonide modulates the permeability and adhesion of 
human choroidal endothelial cells in culture.  Penfold et al49., demonstrated 
that cytokine induced expression of intracellular adhesion molecule -1 is down 
regulated  by  triamcinolone  acetonide  and  interferon  gamma  induction  of 
vascular permeability was decreased by triamcinolone acetonide. 
Wang et al50., demonstrated that matrix metalloproteinase were down 
regulated following incubation with triamcinolone suggesting that the active 
remodeling of the extra cellular matrix necessary for neovascularization can 
be inhibited. 
Wilson et al51demonstrated that a single injection of triamcinolone can 
reduce the severity of blood –retinal barrier breakdown following pan retinal 
photocoagulation. 
Sagamoto  et  al52.,  used  triamcinolone  acetonide  as  a  surgical  tool 
during  pars  plana   vitrectomy  for  complex  diabetic   retinopathy  and 
discovered that in the post operative period the blood ocular barrier was more 
preserved  compared  to  eyes  that  underwent  routine  vitrectomy  without 
intraoperative triamcinolone acetonide.
PROCEDURE OF INTRAVITREAL 
TRIAMCINOLONE INJECTION
             The drug is commonly employed in a dose of 4mg injected in 0.1ml, 
though  some  have  employed  a  dose  of  25  mg  injected  in  0.1  ml41.  The 
commercial  preparation  contains  40mg  in  1ml  with  benzyl  alcohol, 
carboxymethylcellulose  and  polysorbate  80  as  vehicles.  Most 
ophthalmologists would prefer to inject a vehicle free drug. The vehicle may 
be  removed  by  the  process  of  sedimentation  and repeated  washing  of  the 
precipitate with ringer lactate.
            The disadvantage is that the process is not titrated and drug loss can 
occur  while  removing  the  supernatant.  The  final  concentration  of 
triamcinolone  attained  by  such  a  process  is  not  known.  Nishimura  et  al 
devised a technique with the use of two syringe connected by a 3 way valve 
and 0.2 micron filters. The commercial preparation is pushed through the filter 
with no loss of drug and subsequently is reconstituted with saline pushed in 
though the second filter. Recently commercial preparations free of the vehicle 
have been made available (aurocort®).
Technique of Injection:
         The procedure is to be done in the operation theatre with all aseptic 
precautions.  Various  techniques  of  injection  have  been  described.  The 
injection is made through the pars plana route 3mm/3.5mm from the limbus. A 
27G or a 30G needle may be used for the same. 
      Penfold et al., 199517 described injection technique using 30 gauge needle 
through  superotemporal  pars  plana  4.5  mm  from  the  limbus 
Nelson 200353 described using 27 or 30 gauge needle 3.5 mm posterior to the 
limbus in pseudophakic eyes and 4 mm posterior in phakic eyes. Gilles 200318 
used 27 gauge needle Danis 200319 used 30 gauge needle injection performed 
through 6 o ‘clock pars plana  4 mm from the limbus.
       Moshfeghi 200322 used 27, 29 or 30 gauge needle 3mm in pseudophakic 
eyes  and 4  mm in  phakic  eyes  in  inferior  or  inferotemporal  quadrant  and 
aqueous  paracentesis  and  tap  performed  when  necessary.  Jonas  200324 
described  using  3-3.5  mm  from  the  limbus  as  the  injection  site  and 
preoperative paracentesis to reduce iop. Bakri 200327 described a technique of 
using  27  gauge  needle  and  injection  performed  3.5  mm  posterior  to  the 
limbus.
INDICATIONS FOR TRIAMCINOLONE 
ACETONIDE
1. Choroidal neovascular membrane
2. Clinically significant macular edema in diabetes mellitus
3. Macular edema in retinal vein occlusion
4. Cystoid macular edema in pseudophakia
5. Exudative retinal detachment in Vogt Koyanagi Harada syndrome
6. Sympathetic Ophthalmia
7. Idiopathic retinal vasculitis
8. Idiopathic panuveitis
9. Intermediate uveitis
10. Behcet’s disease
11. CME secondary to uveitis not responding to treatment
12. CNVM secondary to serpiginous choroiditis
13. Chronic uveitis
14. Pars planitis
15. Iris neovascularization
ADVERSE EFFECTS OF TRIAMCINOLONE 
ACETONIDE:32
         Various studies were published on the therapeutic effects and adverse 
effects of the intravitreal administration of triamcinolone acetonide. Penfold et 
al.,  1995  reported  cataract  formation  as  the  main  side  effect.  Gilles  2003 
reported  mainly  ocular  hypertension  and  cataract  as  the  adverse  effects. 
Bakri  ,  Danis  reported  mainly  ocular  hypertension  as  the  side  effect  of 
triamcinolone acetonide. Jonas et al in his meta analysis published in 2005 
reported  ocular  hypertension  as  the  most  common  complication. 
Endophthalmitis is one of the dreaded complications of intravitreal injection. 
The  following  studies  were  used  in  calculating  the  prevalence  of 
endophthalmitis.  Moshfeghi  in  2003  reported  8  culture  positive  cases  of 
endophthalmitis. Nelson in 2003 reported 7 cases of pseudoendophthalmitis 
and  2  culture  positive  cases53.  Roth  in  2003  reported  7  cases  of  pseudo 
endophthalmitis.
GLAUCOMA AFTER INTRAVITREAL INJECTION OF 
TRIAMCINOLONE ACETONIDE 
A rise in intraocular pressure is one of the most common of side effects 
following intravitreal  injection of  steroids.26 The mechanism of  increase  in 
intraocular  pressure  is  thought  to  be  due  to  increased  outflow  resistance 
induced by biochemical and morphologic changes in the trabecular meshwork. 
Jonas et  al  noted a rise in 50% of patients  who were given an intravitreal 
injection of 25mg of triamcinolone acetonide. This rise started 1 to 2 months 
after the intravitreal injection.26 IOP rises have been reported as early as 1 day 
following intravitreal  injections.  While  many of  these patients  have only a 
moderate  rise  in  IOP,  some  patients  may  have  a  severe  rise.  Bakri  et  al,  
reported a severe rise in IOP in 27.9%27.  The time-response relationship of 
steroid-induced ocular hypertension has important implications in deciding the 
frequency of follow-up. The post injection rise in IOP is very variable and 
may occur at different times of follow-up. This means that unless the follow-
up is frequent, this rise may well be missed.26 
         Kaushik et al, reported a higher frequency with glaucoma occurring in 
seven out of nine patients treated for cystoid macular edema following CRVO. 
One patient  had glaucoma resistant  to  maximally  tolerated medication  and 
required pars  plana vitrectomy to remove the  steroid  to  control  the  IOP.29 
Chew and associates had reported that young patients with CRVO had wide 
diurnal swings in IOP and were predisposed to develop steroid induced ocular 
hypertension.  This  is  of  concern as such a rise  would further  compromise 
retinal perfusion in these patients 54. 
Gillies in a study of intravitreal triamcinolone injected in a dose of 4mg 
to patients with classic neovascular age-related macular degeneration, noted a 
significant rise in IOP in twenty one of 75 eyes (28%), compared with one of 
76 placebo-treated patients (1.31%). A severe rise of IOP occurred in only two 
patients. All patients achieved good control with topical medications. A single 
medication sufficed in eighteen of these eyes while the other three required 
two medications. He observed that adverse events were also noted in patients 
injected with triamcinolone acetonide injected into the posterior subtenon’s 
space which by far is considered to be the safest route of injection with IOP 
rise occurring in 30% of patients.18
         Antcliff used an injection of 2mg of triamcinolone acetonide in six 
patients with cystoid macular edema secondary to uveitis resistant to other 
routes of steroid administration and cyclosporine A. Patient 2 who had CME 
initially  responsive  to  systemic  steroids  developed  a  rise  in  intraocular 
pressure starting one week after injection. The pressure rose to 40mmHg and 
was resistant to topical and systemic medications and underwent an uneventful 
trabeculectomy.  The  trabecular  meshwork  showed  necrotic  tissue  with  no 
deposition of triamcinolone acetonide on histopathological examination. The 
raise in IOP may not be associated with the dose used11.
Suggested mechanisms of the corticosteroid induced 
increase in intraocular pressure:55
Corticosteroids  are  believed  to  decrease  outflow  by  inhibiting 
degradation of extra cellular matrix material in the trabecular meshwork (TM), 
leading  to  aggregation  of  an  excessive  amount  of  the  material  within  the 
outflow channels and a subsequent increase in outflow resistance two patterns 
of extra cellular deposition have been described in the TM of Steroid-induced 
glaucoma  patients;  fingerprint-like  deposition  of  material  in  the  uveal 
meshwork, and accumulation of fine fibrillar material in the juxtacanalicular 
region.  The  response  might  be  due  to  an  alteration  of  the  metabolism of 
mucopolysaccharides,  leading  to  their  accumulation  in  the  TM.  It  was 
proposed  that  corticosteroids,  which  stabilise  lysosomal  membranes,  could 
reduce  the  release  of  lysosomal  hyaluronidase,  this  resulting  in  a  relative 
inhibition of hyaluronate depolymerisation. The subsequent accumulation of 
mucopolysaccharides  could,  it  was  suggested,  cause  retention  of  water 
(‘biological  edema’)  and  subsequent  narrowing  of  the  trabecular  spaces. 
Support for a steroid-induced effect within the outflow. Channels have come 
from  animal  studies,  experiments  with  cultured  human  TM  cells  and 
perfusion-cultured donor eye models.
In rabbit eyes glucocorticosteroid receptor concentration has been 
shown to be high in ocular tissue and intravenously administered steroid has 
been
found to bind specifically to the nuclei of cells in the outflow channels in a 
similar manner to the binding of Dexamethasone reported to occur in  cultured 
human  TM  cells  Glucocorticocoids  have  been  shown  to  alter  TM  cell 
morphology by causing an increase in nuclear size and DNA content A further 
study has shown that steroids also induce proliferation and activation of the 
endoplasmic  reticulum,  Golgi  apparatus,  and  increase  deposition  of  extra 
cellular  matrix  material.  The  amounts  of  glycosaminoglycans,  elastin  and 
fibronectin  have  been  shown  to  increase  in  tissue  culture  preparations  in 
response to dexamethasone treatment while the levels of tissue plasminogen 
activator, stromelysin, and the activity of several TM metalloproteases have 
been  shown  to  fall.  Furthermore,  excessive  accumulation  of 
glycosaminoglycans  has  been  identified  in  human  trabecular  meshwork 
specimens obtained from steroid responders 
In  support  of  the  evidence  for  extra  cellular  matrix  deposition, 
dexamethasone treatment has also been shown to inhibit TM cell arachadonic 
acid  metabolism and reduce  phagocytic  activity  TM cells  have phagocytic 
properties, the function of which is to clear the outflow channels of debris. A 
steroid-induced inhibition of phagocytosis within the meshwork could result 
in  accumulation  of  channel  debris  and  decreased  facility  of  outflow  so 
contributing to steroid-induced Glaucoma. Structural changes in the TM cells 
have also been proposed.
Clark  et  al60 discovered  that  dexamethasone  caused cross-linkage of 
actin fibres leading to the formation of networks within cultured human TM 
cells.  The  actin  network  structure  was  reversible  following  cessation  of 
corticosteroid administration to the human TM cultures. It was suggested that 
the response might be mediated by the TM glucocorticoid receptor. However, 
the effect of such an alteration of cellular cytoskeleton on TM cell function 
remains unclear.
Clark et al56 went on to demonstrate histological and pressure changes 
in steroid treated, perfusion-cultured human eyes. IOP was measured using a 
pressure transducer within the eye, so that the measurement was not affected 
by corneal thickness. In those eyes in which there was a pressure increase, 
morphological changes included thickened trabecular beams, decreased 
Intertrabecular  spaces,  thickened  juxtacanalicular  tissues,  and  increased 
amounts of amorphous granular extra cellular material. In another perfusion-
cultured human eye model glycosaminoglycans deposition in the meshwork 
increased with increasing duration of steroid exposure.
It  is hoped that recent advances in novel molecular genetic methods 
will  allow  a  better  understanding  of  the  mechanisms  causing  the  steroid-
induced glaucoma. By gene deletion or over expression studies, the exact role 
of individual genes responsible for the modulation of meshwork extra cellular 
material may be identified in the near future.
MANAGEMENT OF CORTICOSTEROID-
INDUCED GLAUCOMA
Monitoring of IOP
A  baseline  measurement  of  IOP  should  be  taken  prior  to 
commencement  of  corticosteroid  therapy.  Increase  in  intraocular  pressure 
occurs  transiently  and gets  controlled  once  the  drug is  stopped in  case  of 
topical medication. In case of subtenon’s and intravitreal administration the 
rise occurs slowly and persists  for  a long time hence monitoring of  lop is 
mandatory in these patients. 
In about 3% of cases and in particular when there is a family history of 
glaucoma and/or chronic use of steroid, the ocular hypertensive response has 
been shown to be irreversible. The management of such cases is no different  
from that for POAG.
Medical anti glaucomatous therapy
Beta-blockers
Topical  beta-blockers  can  be  used  to  control  corticosteroid-induced 
glaucoma, preferably following cessation of steroid therapy and are a popular 
first-line agent for the condition.
Prostaglandin analogues 
Concomitant latanoprost has been shown to be as effective as cessation 
of therapy in controlling the IOP rise associated with corticosteroids so can be 
useful if steroid treatment must be continued. However, latanoprost has been 
reported to induce Uveitis and is relatively contraindicated in eyes with uveitic 
glaucoma. Latanoprost  has been shown to cause cystoid macular edema in 
certain pseudophakic eyes in the early postoperative period (when steroids are 
likely  to  have  been  prescribed.  So  caution  should  be  exercised  when 
prescribing prostaglandin analogues in such eyes.
Alpha agonists 
Brimonidine  can  be  useful  in  many  patients  with  steroid-induced 
glaucoma, although there have been reports of Brimonidine-induced uveitis in 
a minority of patients
Carbonic Anhydrase Inhibitors :
Oral acetazolamide is an effective short-term treatment for the control 
of IOP in all forms of glaucoma, including that induced by corticosteroids. 
Over longer periods, the side effect profile of acetazolamide tends to make it 
poorly tolerated and it is contraindicated in certain patients, such as those with 
renal  impairment.  However,  topical  carbonic  anhydrase  inhibitors 
(dorzolamide  and  brinzolamide)  are  of  use  in  the  control  of  IOP  due  to 
corticosteroid induced Glaucoma.
Argon Laser Trabeculoplasty (ALT)
Jonas  et  al  57,58has  suggested  ALT  as  one  standard  procedure  for 
controlling intravitreal induced ocular hypertension.
Filtration surgery59
Trabeculectomy remains an effective treatment for glaucoma in those 
patients  who  have  a  persistently  raised  IOP  following  cessation  of 
corticosteroid  therapy  and  are  refractory  to  medical  therapy.  However,  as 
always,  the  adverse  consequences  of  trabeculectomy  or  other  forms  of 
drainage surgery should be considered in relation to the potential benefits. It 
seems unlikely that a steroid response occurs following successful filtration 
surgery.  If  one  wants  to  maintain  the  positive  therapeutic  effect  of 
triamcinolone acetonide and if, simultaneously, one has to treat IOP elevation, 
filtering  surgery  may be a  good option.  According to  previous  small  case 
series  studies,  filtering  surgery  in  eyes  with  intravitreal  triamcinolone 
acetonide may have a positive surgical and functional outcome and still leaves 
the triamcinolone acetonide in the eye One has to take into account, however, 
that  after  filtering  surgery  the  duration  of  the  intraocular  availability  of 
triamcinolone acetonide may be reduced due to a  possibly higher  turnover 
rate.
Pars Plana Vitrectomy60: 
PPV may be another treatment option considering that the cause of rise 
in  IOP  is  the  persistence  of  tricort  depot.  The  removal  of  triamcinolone 
acetonide will be combined with the disadvantage that the beneficial effect of 
intravitreal triamcinolone acetonide will soon be terminated after the PPV. A 
therapeutic  advantage  of  a  pars  plana  approach  may  be  the  relief  of 
vitreoretinal traction on the macula, which may lead to a decrease in macular 
edema in patients with diabetic macular edema and epiretinal membranes This 
advantage  must  be  compared  with  the  surgical  risk  of  PPV.In  the  future, 
subtenon anecortave acetate may play a role in the treatment of triamcinolone 
acetonide–induced  ocular  hypertension,  because  it  has  been  said  that 
anecortave acetate may be able to reverse steroid-induced ocular hypertension 
(Robin A, personal communication, 2005).
AIMS AND OBJECTIVES
       To study the effect of intravitreal triamcinolone on intraocular pressure in 
eyes with no preexisting evidence of glaucoma.  
INCLUSION CRITERIA:
       Patients with progressive decrease in visual acuity due to 
                     1. Exudative age related macular degeneration with
                         subfoveal neovascularisation
                                2. Diffuse diabetic macular edema
                                3. Macular edema due to central retinal vein occlusion, 
                                    branch retinal vein occlusion.
                                4. Cystoid macular edema following cataract surgery.
                                5. Macular edema following laser treatment.
EXCLUSION CRITERIA: 
Patients with pre existing glaucoma and others like irregular cornea. 
MATERIALS AND METHOD
    
It  was  a  prospective  consecutive  non  comparative  interventional  case 
series study conducted in Aravind eye hospital and includes all patients with 
diffuse  diabetic  macular  edema,  cystoid  macular  edema  following  cataract 
surgery, macular edema due to central retinal vein occlusion ,branch retinal 
vein  occlusion,  macular  edema  following  laser  treatment,  exudative  age 
related macular degeneration with sub foveal neovascularisation.
      
Treatment was with intravitreal triamcinolone acetonide after obtaining 
informed consent from all the patients. Intraocular pressure measured before 
the procedure and after the procedure and at one month, three months and six 
months by Goldman applanation tonometer.
All  the  patients  had  undergone  comprehensive  ophthalmic  workup 
including testing visual acuity, baseline intraocular pressure measurement by 
Goldmann  applanation  tonometer,  slit  lamp  evaluation  gonioscopy  and 
indirect ophthalmoscopy.
             Other investigations like FFA, OCT were done in majority of our  
patients to document macular thickness and patients had undergone evaluation 
for their systemic illnesses. 
 Treatment:
             The procedure of intravitreal triamcinolone acetonide injection was  
performed  in  operation  theatre  under  aseptic  conditions.  The  eyes  were 
prepared with topical anesthetic agent (paracaine), painted with povidone 
Iodine cleaned and draped. 0.1 ml containing 4 mg of commercially available 
triamcinolone acetonide was injected into the vitreous cavity using 26 gauge 
needle through pars plana 3 mm from the limbus in case of aphakia, 3.5 mm in 
pseudophakia, 4 mm in phakic eyes.
             At the end of procedure optic nerve head perfusion and central retinal 
artery pulsation were checked with indirect ophthalmoscopy and intraocular 
pressure  digitally.  In  case  of  digitally  raised  intraocular  pressure  and/or 
presence of central  artery pulsation paracentesis  done to reduce intraocular 
pressure. Sterile pad and bandage applied at the end of procedure.
              The patients were reviewed on the same day evening and they were 
subjected to slit lamp evaluation for presence of tricort crystals and intraocular 
pressure  was measured using Goldmann applanation tonometer.  In  case  of 
elevated  intraocular  pressure  the  patients  were  evaluated  in  our  glaucoma 
clinic. The patients without rise in intraocular pressure were advised to use 
antibiotic eye drops for one week and advised to review after one month.
 Follow up:
Our patients were regularly followed up in retina clinic at 1 month, 3 
months  and  6  months.  In  each  visit  patients  underwent  vision  testing, 
intraocular  measurement  using  Goldmann applanation  tonometer,  slit  lamp 
evaluation and indirect ophthalmoscopy. FFA and OCT were advised in their 
follow up visits to document macular thickness and done in patients who were 
willing  to  undergo  these  investigations.  Those  patients  with  increased 
intraocular pressure were followed up in glaucoma clinic also. The above data 
were entered in standard form and transferred to an electronic database and 
subsequently analyzed.  
 
Data collection and outcomes :   
            Patients were seen at one, three, six months and data on intraocular 
pressure and management of increased intraocular pressure were entered on to 
the standard data collection form and transferred on to an electronic data base. 
             This case series study included 94 eyes of 94 patients of which 59 
were males and 35 were females.  Mean age of the study group was 58.03 
years (Standard deviation (S.D) = 11.67) .Among these 94 patients 12(12.8%) 
were less than or equal to 45 years.27 were in the age group of 46-55 (28.7%). 
30 were in the age group of 56-65 (31.9%).25 (26.6%) were in the age group 
of more than or equal to 66 years.
81.5%  (n=53)  of  cases  had  diabetic  mellitus,  41.5%  (n=27)  had 
hypertension, 7.75 (n=50) had renal disease, 6.2% (n=40) had cardiac disease. 
All these patients received 4 mg of triamcinolone acetonide as a treatment for 
diabetic macular edema in 29 patients (30.9%), 22 patients for central retinal 
vein occlusion (23.4%),  32 patients for exudative macular edema (34%), 6 
patients for post operative cystoid macular edema (6.4%), and 5 patients for 
branch retinal vein occlusion (5.3%).
           
All the patients were fully informed about the experimental nature of 
the treatment and all the patients had signed an informed consent. In this study 
none of the patients had primary open angle glaucoma, chronic closed angle 
glaucoma or ocular hypertension.
All  the  patients  received  an  intravitreal  injection  of  4  mg  of 
triamcinolone acetonide as previously described. None of the eyes received 
steroids either topically or systemically following treatment.
           
At  the  baseline  of  the  study  intraocular  pressure  the  mean baseline 
being 15.03 ± 2.989 mm Hg, the range being 10 -20 mm Hg. If the intraocular 
pressure exceeded 21 mm Hg topical beta blockers and/or carbonic anhydrase 
inhibitors  were  started  as  the  medication  of  first  choice.  If  the  initial 
intraocular  pressure  was  very  high  then combination  of  both were  started. 
Filtering surgery was indicated if intraocular pressure continued to be higher 
despite  maximal  medical  therapy  and  development  of  glaucomatous  optic 
neuropathy.
RESULTS 
In the  study group mean intraocular  pressure  increased significantly 
(p=0.000) after the intravitreal triamcinolone injection from 15.03 ± 2.989 mm 
Hg to 23.65 ± 11.226 mm Hg, during follow up. The mean rise in intraocular 
pressure  was  8.62  ±  10.647  mm  Hg, with  the  proportion  increase  being 
59.03%
            Rise in intraocular pressure is defined as measurements outside the 
normal range at least one IOP measurement higher than 21 mm Hg.  Increased 
IOP was observed in 31 patients in this series. Increase in IOP is defined as 
the difference between maximal postoperative IOP and baseline IOP. Mean 
increase in IOP for the entire study group was 8.62 ± 10.647 mm Hg.
            The entire study group is divided into two subgroups as triamcinolone 
responders and triamcinolone non responders. Predictive factors for increased 
IOP  were  analyzed.  The  subgroups  did  not  vary  significantly  in  gender 
(p=0.508).  Ocular  condition  for  which  intravitreal  triamcinolone  was 
administered was analyzed. The mean IOP increased significantly (p=0.024) 
in case of diabetic macular edema. Among the systemic condition diabetes 
mellitus showed a significant association (p=0.045) though logistic regression 
failed to prove a significant correlation with either of the two.
          The mean maximal IOP vary significantly with the mean baseline iop 
(p=0.000).Among the triamcinolone responders the mean baseline IOP was 
15.71 ± 2.912 mm Hg, and the mean maximal IOP was 36.74 ± 10.689 mm 
Hg with the proportion increase being 136.94%.
               Of the 94 patients,  31 showed increased intraocular pressure 
following treatment with intravitreal triamcinolone.71% of the triamcinolone 
responders had a baseline IOP of greater than or equal to 15mm Hg and 29% 
had  base  line  IOP  less  than  15  mm  Hg.  Among  the  triamcinolone  non 
responders 46% had IOP greater than or equal to 15mm Hg and 54% had IOP 
less than 15 mm Hg. Overall the baseline IOP showed a positive correlation 
with the increase in IOP (P=0.01) and the risk of increased IOP is 2.06 times 
more for the patients with the baseline IOP greater than or equal to 15 mmHg 
than the patients with the base line IOP of less than 15 mm Hg.
           The mean time of increase in IOP is 2.9 ± 1.921 months. Mean IOP at 
the end of 6 months being 24 ± 13.14 mm Hg. Increase in IOP was observed 
in the immediate post treatment period in 8.3% of patients in less than or equal 
to 45 years age group, 11.1% in 45-55 years age group, 23.3% in 56-65 years 
age group and none in more than 66 years age group. Follow up at one month 
showed 40% of  patients  in  less  than  or  equal  to  45  years  age  group  had 
increase in IOP, 25.9% of 46-55 years , 30% of 56 -65 years age group and 
8% of more than 66 years age group. Follow up at 3 months showed that 50% 
of patients in less than or equal to 45 years had increase in IOP , 22.2% in 46-
55 years age group, 28.6% in 56-65 years age group. Follow up at 6 months 
showed that 30% had increase in IOP in less than or equal to 45 years ,8% in 
46 -55 years age group 25% in 56-65 years  and 5% in more than 66years age 
group. The increase in IOP tend to occur more in younger age group and it 
persisted for a longer period (p=0.005).  Incidence of increased IOP in first 
month was 23.9%, third month was 6.9% and sixth month was 3.6%
              31 of 94 patients had increase in IOP in this study (33%). Out of 31  
patients 8 were treated initially with combination therapy (25.80%) and  23 
patients  received monotherapy  (74.12%) within  6  months  of  study period. 
45%  were  successfully  treated  with  medications  and  discontinued 
medications.45 % required medications at the end of 6 months to keep IOP 
under control. One patient underwent trabeculectomy (3.225%) and 2 patients 
required anterior retinal cryopexy (6.45%).
TABLES AND FIGURES
AGE 
Frequency Percent 
< = 45 12 12.8
46-55 27 28.7
56-65 30 31.9
> = 66 25 26.6
Total 94 100.00
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SEX
Frequency Percent 
Male 59 62.8
Female 35 37.2
Total 94 100.0
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SYSTEMIC DISEASE
  
                           
Count Percentage 
Diabetic Mellitus 53 81.5
Hypertension 27 41.5
Hyperlipidemia 1 1.5
Renal disease 5 7.7
Cardiac 4 6.2
Asthma 1  1.5
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Systemic Factors
OCULAR DISEASE 
Frequency Percent 
DME  29 30.9
C ME 6 6.4
CRVO 22 23.4
BRVO 5 5.3
CNVM 32 34.0
Total 94 100.0
Ocular Disease
31%
6%
23%
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35%
DME
CME
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BRVO
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Descriptive Statistics on Age for the entire study group 
(in years)
 
N Range Minimum Maximum Mean Std.Deviation
Age 94 55 27 82 58.03 11.693
Descriptive Statistics on Baseline IOP for the entire study group 
(in mm Hg)
N Range Minimum Maximum Mean Std.Deviation 
Baseline IOP 94 10 10 20 15.03 2.989
Descriptive Statistics on Characteristics of IOP for the entire study group 
following treatment  
N Range Minimum Maximum Mean Std. Deviation 
Baseline IOP 94 10 10 20 15.03 2.989
IOP range 94 62 12 74 23.65 11.226
Last follow up 
IOP
94 64 10 74 18.03 8.922
Time of IOP rise 
( in months)
94 5 1 6 2.72 1.750
Proportion 
Increase (%)
94 282.50 -12.50 270.00 50.036
2
67.340
Amount of IOP 
rise 
94 56 -2 54 8.62 10.647
Ocular Hypertension following treatment
33%
67%
Increased IOP
Normal IOP
OCULAR HYPERTENSION FOLLOWING TREATMENT
Frequency Percent 
Increase in IOP 31 33.0
No increase in IOP 63 67.0
Total 94 100.0
Descriptive Statistics on Characteristics of IOP for triamcinolone 
responders 
N Range Minimum Maximum Mean Std. Deviation 
Baseline IOP 31 10 10 20 15.71 2.912
IOP range 31 52 22 74 36.74 10.689
Last follow up 
IOP
31 63 11 74 24.00 13.148
Time of IOP rise 
( in months)
31 5 1 6 2.90 1.921
Proportion 
Increase ( %)
31 220.00 50.00 270.00 136.96 57.68
Amount of IOP 
rise 
31 46 8 54 21.03 9.731
Post Treatment IOP
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Increase in IOP was observed in the immediate post treatment period in 
8.3% of patients in less than or equal to 45 years age group, 11.1% in 45-55 
years age group, 23.3% in 56-65 years age group and none in more than 66 
years age group.
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Follow up at 1 month
Percentage 
Follow up at one month showed 40% of patients in less than or equal to 
45 years age group, 25.9% of 46-55 years , 30% of 56 -65 years age group and 
8% of older than 66 years age group had increase in IOP
Follow up at 3 months
50%
22%
28%
>=45 46-55 56-65
Follow up at 3 months showed that 50% of patients in less than or 
equal to 45 years , 22.2% in 46-55 years age group, 28.6% in 56-65 years age 
group had increase in IOP 
Follow up at 6 months
44%
12%
37%
7%
>=45 46-55 56-65 >=66
Follow up at 6 months showed that 30% in less than or equal to 45 
years, 8% in 46 -55 years age group, 25% in 56-65 years and 5% in more than 
66years age group had increase in IOP
MANAGEMENT OF INCREASED IOP 
        Total No. of Cases with ↑ IOP 
   (n =31)
       ↓
Combination therapy     Mono therapy 
   (n = 8)           (n = 23) 
Successfully    Not Successful    
 Treated               (n = 6)
 (n = 2)
           Surgery           Continue same drug
              (n=1)                       (n=5)                                Combination 
Continue 
                                                                                            therapy              same 
                                                                                                                      drug 
          (n=5)  
(n=6)
      Successfully    Not Successful    
          Treated               (n = 11)
           (n=12)
DISCUSSION
The  aim  of  this  study  was  to  analyze  the  effects  of  intravitreal 
triamcinolone  on  IOP and to  find  out  the  baseline  characteristics  that  can 
cause increase in IOP.
Variables that were analyzed in this study included age gender systemic 
disease, ocular condition for which the drug was administered, baseline IOP.
           Age proved to be an important determinant in the development of  
increased  intraocular  pressure  (p=0.005)  increased  IOP  tend  to  occur  in 
younger age group than the older age group and persists for a longer time. At 
the end of one month follow up 40% of the patients aged less than or equal to 
45 years showed an increase in IOP. At the end of 3 months 50% had increase 
in  IOP,  and  at  6  months  30%  had  increase  in  IOP.  The  mean  age  of 
triamcinolone responders in other studies were relatively high compared to 
this study group. Though Jonas et al., found a tendency of increased IOP in 
younger age group their mean age of triamcinolone responders was 71.3 ± 9.9 
years which was very high compared to this study. Smithen et al., did not find 
any correlation with age.
           
Increase in intraocular pressure did not show any variation with gender. 
Though increased IOP showed significant variation with regard to diabetes 
mellitus and diabetic macular edema logistic regression failed to show any 
positive  correlation  .So  diabetes  might  not  be  a  contraindication  for 
intravitreal injection which was proved in other studies also.
           
        Increase in IOP showed a positive correlation with the base line IOP. 
Patients  who had higher  baseline  IOP tend to  have increased incidence of 
intraocular pressure elevation (relative risk being 2.06 and p value 0.023).The 
mean time of IOP rise occurred in 2.9±1.921 months. The incidence of ocular 
hypertension was highest in 1st month (23.9%) in 3rd month was 6.9% and in 
6th month being 3.6%
 90% of the patients did not have progressive optic nerve head damage 
and IOP was controlled by medical measures alone. One out of 31 patients 
required trabeculectomy because of progressive optic nerve head damage and 
two required ARC for retinal neovascularisation.
STRENGH OF THE STUDY:
• Prospective study.
• 4mg of triamcinolone acetonide was used 
• None of the cases had repeat injection during the study period.
• None of the cases had glaucoma at the baseline
• Only one eye of a single patient was included in the study.
LIMITATIONS OF THE STUDY: 
1. Small sample size. 
Though there was significant variation with age and occurrence 
of  increased IOP, since the no. of patients were very less the results 
could not be generalized and further studies are required to determine the 
age limit for intravitreal triamcinolone acetonide.
2. Baseline IOP 
Since baseline  IOP was  determined on a  single  measurement 
taken by different persons at  different  time of time of the day which 
might  not reflect the true baseline IOP.
3. Follow up period 
Follow up period was 6 months while intravitreal triamcinolone 
might persist in the eye for more than 9 months.
CONCLUSION
A  prospective study on 94 eyes after the administration of a single 
dose of intravitreal triamcinolone acetonide showed that 
1. Incidence of IOP elevation was 33%
2. Mean time of increase of IOP was 2.9 months.
3. Incidence of ocular hypertension  in 1st month was 24%
4. Age and baseline IOP could be the positive predictive factors.
5. 90% of the cases were controlled with medical therapy.   
IOP elevation was transient and 90% of cases did not have optic nerve 
head changes and elevated IOP was controlled with medications.
                  
PROFORMA
EFFECTS OF INTRAVITREAL TRIAMCINOLONE ON 
INTRAOCULAR PRESSURE
PATIENT INFORMATION:
a. Name:
b. Age   :
c. Sex    :               Male                           Female
d. MR.No :                                                              Serial no:
SYSTEMIC DISORDERS:
  
a. Diabetic mellitus  :
b. Hypertension        :
c. Hyperlipidemia     :
d. Renal disease        :
e. Others                    :                                     (if any specify)
FAMILY HISTORY OF GLAUCOMA :
PAST HISTORY OF INCREASED IOP DUE TO TOPICAL 
STEROIDS:
OCULAR CONDITION FOR WHICH INTRAVITREAL TRICORT 
GIVEN:
a. Diabetic macular edema :
b. Cystoid macular edema   :
c. Macular edema due to 
                         CRVO         :
                         BRVO         :
d. CNVM                             :
DETAILS OF EXAMINATION:
a. Visual acuity   :      RE
                                   LE
b. Best corrected visual acuity  :       RE
                                                           LE
c. Intraocular pressure   :         RE
                                                 LE
                     
  d. Fundus examination: 
      
                                         RE                                         LE
     1. Disc:
          CDR
          NRR
          RFNL
     2. Vessels:
     3. Macula:
         
    
DATE OF ADMINISTRATION OF TRICORT:
POST TREATMENT IOP:                            
 
     Effects of Intravitreal Triamcinolone on Intraocular pressure 
Indication for Triamcinolone Use:
1. Episode
1 month          3 month            6 months
2. Baseline Intraocular Pressure    3A.Study eye 
              Right eye              Left eye
                 mmHg                mmHg   
3A.Intraocular pressure at follow up                         
 
1 month 3 months 6 months
Right eye
Left eye
      3B.Visual acuity:
1 Month 3 months 6 months
Right eye
Left eye
 4. Medication Started:     
                     Yes                         No
   (i) If Yes:                         A.                          B.                        C              
                               Strength               Frequency         Date Initiated   
       1. Timolol         0.25% 0.5%             
 2. Brimonidine  0.2% 0.15%
  (ii) Four weeks follow-up
        IOP under control                 
        IOP Drop not satisfactory     No IOP drop
   (iii) IOP drop not adequate with medications       
Success- continue till 
6 months follow up
Add:
Week 4: …………….
              ……………..
  ………….....
Week 8: …………….
              …………….
             ……………...
Substitute:
Week 4 : …………….
    …………….     
Week 8 :  …………….
     …………….
    ……………..
Consider trabeculectomy
a) With Mitomycin C
b) Without Mitomycin C
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